Expertise in
14
conditions

Dr. Ann Gillenwater

General Surgery
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
14
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Ann Gillenwater is a General Surgeon in Cary, North Carolina. Dr. Gillenwater is highly rated in 14 conditions, according to our data. Her top areas of expertise are Leukoplakia, Tongue Cancer, Oral Squamous Cell Carcinoma, Gastrostomy, and Tissue Biopsy.

Her clinical research consists of co-authoring 53 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

General Surgery

Licenses

Otolaryngology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518
Other Locations
Office
1515 Holcombe Blvd Unit 1445, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Enrollment Status: Recruiting
Publish Date: January 14, 2026
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 2/Phase 3
Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders
Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug, Procedure
Study Phase: Early Phase 1
Fluorescence & Reflectance Imaging to Detect Oral Neoplasia
Fluorescence & Reflectance Imaging to Detect Oral Neoplasia
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Other
Study Phase: Not Applicable
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 19, 2025
Intervention Type: Combination product, Biological
Study Drugs: Pembrolizumab, Cemiplimab
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug, Combination product
Study Drugs: ASP-1929, Docetaxel, Cetuximab, Methotrexate, Paclitaxel
Study Phase: Phase 3
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Withdrawn
Publish Date: April 19, 2023
Intervention Type: Combination product, Biological
Study Drugs: RM-1995, Pembrolizumab
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Combination product
Study Phase: Phase 1/Phase 2
Fluorescence and Reflectance Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions
Fluorescence and Reflectance Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions
Enrollment Status: Completed
Publish Date: January 19, 2018
Intervention Type: Procedure
Study Phase: Not Applicable
View 8 Less Clinical Trials

53 Total Publications

Chemotherapy alone for stage II-IVa laryngeal squamous cell carcinoma: A 20-year follow-up.
Chemotherapy alone for stage II-IVa laryngeal squamous cell carcinoma: A 20-year follow-up.
Journal: Cancer
Published: August 15, 2025
Similar Doctors
Expertise in
42
conditions
Dr. Ehab Hanna
General Surgery
Expertise in
42
conditions
Dr. Ehab Hanna
General Surgery

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.9 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ehab Hanna is a General Surgeon in Cary, North Carolina. Dr. Hanna is highly rated in 42 conditions, according to our data. His top areas of expertise are Olfactory Neuroblastoma, Adenoid Cystic Carcinoma, Sinus Cancer, Turbinectomy, and Endoscopy.

Expertise in
17
conditions
Dr. Jean Vauthey
General Surgery
Expertise in
17
conditions
Dr. Jean Vauthey
General Surgery

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.9 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jean Vauthey is a General Surgeon in Cary, North Carolina. Dr. Vauthey is highly rated in 17 conditions, according to our data. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Liver Cancer, Hepatectomy, and Hepato-Pancreato-Biliary Surgery.

Expertise in
26
conditions
Dr. Nancy Perrier
General Surgery
Expertise in
26
conditions
Dr. Nancy Perrier
General Surgery

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.9 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Nancy Perrier is a General Surgeon in Cary, North Carolina. Dr. Perrier is highly rated in 26 conditions, according to our data. Her top areas of expertise are Parathyroid Adenoma, Parathyroid Cancer, Hyperparathyroidism, Parathyroidectomy, and Thyroidectomy.

Frequently Asked Questions about Dr. Ann Gillenwater

How do I make an appointment with Dr. Ann Gillenwater?

You can book an appointment with Dr. Ann Gillenwater by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ann Gillenwater a top-rated expert for Leukoplakia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ann Gillenwater is classified as an Distinguished expert for Leukoplakia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ann Gillenwater specialize in?

While Dr. Ann Gillenwater is a General Surgery, they have specific expertise in Leukoplakia, Tongue Cancer, and Oral Squamous Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Surgery.

Does Dr. Ann Gillenwater participate in research or clinical trials?

Yes. Dr. Ann Gillenwater has published 53 articles and abstracts on conditions like Leukoplakia. You can view a list of Dr. Ann Gillenwater's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ann Gillenwater accept my insurance?

Dr. Ann Gillenwater accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gillenwater's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile